Carlos R. Camozzi
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Carlos R. Camozzi
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
14
| Extinct | Miscellaneous Commercial Services | 14 |
| Public Company | Pharmaceuticals: Major | 5 | |
Syndermix AG
 Syndermix AG Household/Personal CareConsumer Non-Durables Syndermix AG manufactures skin and beauty care products. The private company is based in Nidwalden, Switzerland and has subsidiaries in Switzerland.
3
| Private Company | Household/Personal Care | 3 |
Simbec-Orion Group Ltd.
 Simbec-Orion Group Ltd. Pharmaceuticals: MajorHealth Technology Simbec-Orion Group Ltd. provides contract research services for rare and orphan conditions. The firm offers services for oncology, orphan diseases, respiratory, dermatology, infectious vaccines and diseases. The company was founded in 2014 and is headquartered in Pentrebach, the United Kingdom.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Carlos R. Camozzi
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| UNIQURE N.V. | Biotechnology | Director/Board Member Chairman Founder Founder Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| University of Groningen | College/University | Doctorate Degree Undergraduate Degree | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman | |
| ESGTI AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
| University of Zurich | College/University | Doctorate Degree Graduate Degree | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Impella Cardiosystems AG
 Impella Cardiosystems AG Medical SpecialtiesHealth Technology Impella Cardiosystems AG develops, manufactures, and markets minimally invasive cardiovascular support systems. The company is based in Aachen, Germany. The German company was founded by Thorsten Sieß. | Medical Specialties | Director/Board Member | |
| Swissair Beteiligungen AG | Chairman | ||
| First Catering Produktions AG | Corporate Officer/Principal | ||
| Hiestand International AG | Director/Board Member | ||
Asserta Asset Management AG
 Asserta Asset Management AG Investment ManagersFinance Part of Cat Holding AG, Asserta Asset Management AG is a Swiss independent asset management company that exclusively represents the interests of its clients. The company is based in Zurich, Switzerland. The CEOs are Marcel Gehrig, Nicolaus Bönheim. The company was founded in 1978. | Investment Managers | Chairman | |
| Eventagentur.ch AG | Corporate Officer/Principal | ||
| ARYZTA AG | Food Retail | Director/Board Member | |
Grand Resort Bad Ragaz AG
 Grand Resort Bad Ragaz AG Hotels/Resorts/Cruise linesConsumer Services Grand Resort Bad Ragaz AG engages in the operation of luxury hotels. It operates through the following segments: Resort, Tamina Therme, Casino and Clinic Bad Ragaz. The company was founded in 1242 and is headquartered in Bad Ragaz, Switzerland. | Hotels/Resorts/Cruise lines | Chairman | |
Cat Holding AG
 Cat Holding AG Financial ConglomeratesFinance Cat Holding AG engaged in asset management and advisory services. It provides fund management and fund distribution and tailored solutions in the area of structured products for external asset managers. The company as founded in 1988 and is headquartered in Zurich, Switzerland. | Financial Conglomerates | Director/Board Member | |
| Fachhochschule Frankfurt Am Main | College/University | Undergraduate Degree | |
SAirRelations
 SAirRelations RestaurantsConsumer Services SAirRelations provides catering services to air travelers. The private company is based in Bern, CH. and has subsidiaries in Finland, United Kingdom, Austria and Switzerland. | Restaurants | Chief Executive Officer | |
| Casino Bad Ragaz AG | Chairman | ||
Nimo Holding AG
 Nimo Holding AG Financial ConglomeratesFinance Nimo Holding AG is an investment holding Swiss company. The private company is based in Bassersdorf, Switzerland. | Financial Conglomerates | Director/Board Member | |
| Quade & Zurfluh AG | Director/Board Member | ||
| Casino Admiral AG | Director/Board Member | ||
| Quantrum AG | Founder | ||
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
LSG Airline Catering & Retail GmbH
 LSG Airline Catering & Retail GmbH RestaurantsConsumer Services LSG Lufthansa Service Holding AG provides in-flight catering and logistic services. It offers catering services; onboard retail services; equipment, including meal-service products, commodities, comfort items, and galley inserts; lounge management services, including cleaning, provisioning, maintenance, reception, and more; logistics and supply-chain management services; and innovation and consulting services in the areas of menu design, food and service presentation, sales, ancillary retail, product design, and more. The company serves airlines, train operators and retailers. LSG Lufthansa Service Holding was founded in 1966 and is headquartered in Frankfurt am Main, Germany. | Restaurants | Corporate Officer/Principal | |
| Amt NV | Chairman | ||
Forbion Co-Investment II Coöperatief UA
 Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Investment Managers | Founder | |
Alantos Pharmaceuticals Holding, Inc.
 Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Director/Board Member | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman | |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
| Oxyrane, Ltd. | Director/Board Member |
Statistik
International
| Schweiz | 22 |
| Niederlande | 11 |
| Vereinigtes Königreich | 7 |
| Vereinigte Staaten | 6 |
| Deutschland | 5 |
Sektoral
| Health Technology | 14 |
| Consumer Services | 11 |
| Finance | 9 |
| Commercial Services | 3 |
| Transportation | 3 |
Operativ
| Director/Board Member | 111 |
| Corporate Officer/Principal | 46 |
| Director of Finance/CFO | 28 |
| Chairman | 26 |
| Independent Dir/Board Member | 24 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Hugo Slootweg | 34 |
| Ferdinand Verdonck | 25 |
| Wolfgang Heinrich Werlé | 25 |
| Robert Dickey | 23 |
| Joseph Feczko | 23 |
| François Meyer | 20 |
| Piers John Morgan | 18 |
| Sander J. van Deventer | 17 |
| Martin Walton | 16 |
| Hans Preusting | 12 |
| Kevin Cox | 12 |
| Chad C. Hellmann | 8 |
| Subhasis Roy | 8 |
| Jessica Kourniaktis | 7 |
| Philippe van Holle | 6 |
- Börse
- Insiders
- Carlos R. Camozzi
- Unternehmensverbindungen
